| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/04/2004 | EP1386166A2 Anti-epileptogenic agents |
| 02/04/2004 | EP1386163A2 Isolated ductal fluid sample |
| 02/04/2004 | EP1386162A2 Diagnostic and therapeutic methods based on the l1 adhesion molecule for ovarian and endometrial tumors |
| 02/04/2004 | EP1385993A2 Method of detecting and treating tuberous sclerosis complex associated disorders |
| 02/04/2004 | EP1385977A2 Secreted proteins |
| 02/04/2004 | EP1385953A2 Proteins and nucleic acids encoding same |
| 02/04/2004 | EP1385952A2 Methods of inhibiting expression of a target gene in mammalian cells |
| 02/04/2004 | EP1385948A2 Nucleic acids for inhibiting hairless protein expression and methods of use thereof |
| 02/04/2004 | EP1385945A1 Novel mutation |
| 02/04/2004 | EP1385937A1 Delivery of polynucleotide agents to the central nervous sysstem |
| 02/04/2004 | EP1385878A2 Compounds that affect cd83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds |
| 02/04/2004 | EP1385876A2 Gonococcal proteins and nucleic acids |
| 02/04/2004 | EP1385870A2 Peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 02/04/2004 | EP1385868A2 Steroidal derivatives |
| 02/04/2004 | EP1385858A1 Novel 5-thio-ss-d-xylopyranoside derivatives, preparation method thereof, pharmaceutical compositions containing same and the therapeutic use thereof |
| 02/04/2004 | EP1385857A1 Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation |
| 02/04/2004 | EP1385856A2 Amino acid complexes of c-aryl glucosides for treatment of diabetes and method |
| 02/04/2004 | EP1385854A1 Thiazolopyrimidines and their use as modulators of chemokine receptor activity |
| 02/04/2004 | EP1385852A1 Compounds and methods for inhibiting mrp1 |
| 02/04/2004 | EP1385849A1 Novel hydroxy cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists |
| 02/04/2004 | EP1385848A2 Phtalazinones derivatives useful as pde4/7 inhibitors |
| 02/04/2004 | EP1385847A2 Pyrazolo[1,5-a]pyridine derivatives |
| 02/04/2004 | EP1385845A1 N-aroyl cyclic amines |
| 02/04/2004 | EP1385844A1 Oxazolidinones containing a sulfonimid group as antibiotics |
| 02/04/2004 | EP1385843A1 Arylindenopyridines with pde inhibiting activity |
| 02/04/2004 | EP1385842A1 Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands |
| 02/04/2004 | EP1385841A1 Sulfonamides |
| 02/04/2004 | EP1385840A1 Sulfonamides |
| 02/04/2004 | EP1385839A1 3-substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists |
| 02/04/2004 | EP1385838A1 Piperazino-derivatives and their use as pde4 inhibitor |
| 02/04/2004 | EP1385837A1 Tricyclic alkylhydroxamates, their preparation and their use as cell proliferation inhibitors |
| 02/04/2004 | EP1385836A2 Aromatic sulfone hydroxamates and their use as protease inhibitors |
| 02/04/2004 | EP1385835A1 Benzoxazinone derivatives for use in the treatment of angiogenesis |
| 02/04/2004 | EP1385834A1 Bicyclo[3,1,0]hexane containing oxazolidinone antibiotic and derivatives thereof |
| 02/04/2004 | EP1385831A2 Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents |
| 02/04/2004 | EP1385830A1 Sulfonamides |
| 02/04/2004 | EP1385828A1 Compounds of the family of 3-alkyl-(4,5 dipheny-imidazol-1-yl) and their use as soothing agents |
| 02/04/2004 | EP1385827A1 Novel compounds of the family of 3-alkyl-(4,5 diphenyl-imidazol-1-yl) and their use as soothing agents |
| 02/04/2004 | EP1385825A1 Substituted 2-pyridine-cyclohexane-1,4-diamine derivatives |
| 02/04/2004 | EP1385824A2 Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof |
| 02/04/2004 | EP1385823A1 Novel guanidino compounds |
| 02/04/2004 | EP1385822A1 Aminopyrrolidine sulfonamides as serine protease inhibitors |
| 02/04/2004 | EP1385821A2 Novel anti-adhesive compounds and uses thereof |
| 02/04/2004 | EP1385820A1 Anthranilic acid amides, method for the production thereof, their use as antiarrhythmia agents, and pharmaceutical preparations thereof |
| 02/04/2004 | EP1385818A2 Biurethane derivatives |
| 02/04/2004 | EP1385595A2 Processes and apparatus for extraction of active substances and enriched extracts from natural products |
| 02/04/2004 | EP1385578A1 Utilization of rutins and aescins in the treatment of circulatory disturbances of the ear |
| 02/04/2004 | EP1385577A2 Use of nk-1 receptor antagonists against benign prostatic hyperplasia |
| 02/04/2004 | EP1385552A1 Oral delivery method and composition for solid medications or dietary supplements |
| 02/04/2004 | EP1385551A1 Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil |
| 02/04/2004 | EP1385550A2 Therapeutic method for inducing tolerance |
| 02/04/2004 | EP1385549A2 Combination of nateglinide or repaglinide with at least one further antidiabetic compound |
| 02/04/2004 | EP1385548A2 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions |
| 02/04/2004 | EP1385547A1 Binding member which binds to both lewis-y and lewis-b haptens, and its use for treating cancer |
| 02/04/2004 | EP1385546A1 Combination therapy using anti-egfr antibodies and anti-hormonal agents |
| 02/04/2004 | EP1385536A2 Preparations containing a combination of vitamin e and afamin |
| 02/04/2004 | EP1385534A2 Ccr5 antagonist and dp-178 polypeptide for treating viral infections |
| 02/04/2004 | EP1385532A1 Stimulation of osteogenesis using rank ligand fusion proteins |
| 02/04/2004 | EP1385530A1 Formulation of amphiphilic heparin derivatives for enhancing mucosal absorption |
| 02/04/2004 | EP1385529A1 Treatment of refractory tumors using epothilone derivatives |
| 02/04/2004 | EP1385528A2 Disinfecting and solubilizing steroid compositions |
| 02/04/2004 | EP1385527A1 Use of 2-alpha-cyano-4-alpha, 5-alpha-epoxyandrostan-17-beta-ol-3-one derivatives for lowering levels of serum cortisol and for the treatment of clinical conditions associated thereof |
| 02/04/2004 | EP1385526A2 3, 7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure |
| 02/04/2004 | EP1385525A2 Targeted oxidative therapeutic formulation |
| 02/04/2004 | EP1385524A1 Pyrazolopyrimidines as therapeutic agents |
| 02/04/2004 | EP1385523A2 Adenosine a1 receptor antagonists for treating hypoxia-induced learning and memory impairment |
| 02/04/2004 | EP1385522A2 Combination comprising a signal transduction inhibitor and an epothilone derivative |
| 02/04/2004 | EP1385521A2 Pharmaceutical composition containing pde v inhibitors and surfactants |
| 02/04/2004 | EP1385520A2 Methods and compounds for the treating neurologic or neuropsychiatric disorders and identifying compounds to treat the same |
| 02/04/2004 | EP1385519A2 Compounds for treating inflammatory diseases |
| 02/04/2004 | EP1385518A1 Benzimidazolone compounds |
| 02/04/2004 | EP1385517A1 Novel oral general anesthetics and metabolitically resistant anticonvulsants |
| 02/04/2004 | EP1385516A1 The treatment of scarring and related conditions using ppar-gamma activators |
| 02/04/2004 | EP1385515A1 Spiropyrazole compounds |
| 02/04/2004 | EP1385514A1 Spiroindene and spiroindane compounds |
| 02/04/2004 | EP1385513A1 Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents |
| 02/04/2004 | EP1385512A2 Use of pyridoindolone derivatives for preparing anticancer medicines |
| 02/04/2004 | EP1385511A1 Composition comprising antifungal agents for treating vulvovaginitis and vaginosis |
| 02/04/2004 | EP1385510A1 Prodigiosin composition for the treatment of rheumatic arthritis |
| 02/04/2004 | EP1385509A1 Method of treatment |
| 02/04/2004 | EP1385508A1 Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 02/04/2004 | EP1385507A1 Sulfonamides |
| 02/04/2004 | EP1385506A2 Acylated piperidine derivates as melanocortin-4 receptor agonists |
| 02/04/2004 | EP1385505A2 Acne treatment |
| 02/04/2004 | EP1385504A1 Method of inhibiting adhesion formation |
| 02/04/2004 | EP1385503A1 The use of enantiomeric pure escitalopram |
| 02/04/2004 | EP1385502A2 Method for the production of anhydrous, pharmaceutical formulations of xanthogenates |
| 02/04/2004 | EP1385501A2 Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality |
| 02/04/2004 | EP1385500A1 Fatty alcohols and fatty acid esters useful for treatment of inflammation |
| 02/04/2004 | EP1385499A1 Method for improving the well-being of poultry by in-ovo injection of carnitine |
| 02/04/2004 | EP1385498A2 Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors |
| 02/04/2004 | EP1385497A1 Method of preventing or treating breast, prostate and/or cervical cancer with n,n-dimethylglycine |
| 02/04/2004 | EP1385496A2 Use of compositions for treating rosacea |
| 02/04/2004 | EP1385495A2 Sulfonamides |
| 02/04/2004 | EP1385494A2 Aerosol compositions containing formoterol and a steroid such as e.g. budesonide or fluticasone for delivery into the lungs |
| 02/04/2004 | EP1385493A1 Substituted cyclohexan-1,4-diamine derivatives with constipating and peripheral analgesic properties |
| 02/04/2004 | EP1385492A2 Use of hyaluronic acid derivatives for the prevention of inflammatory arthritis |
| 02/04/2004 | EP1385490A1 Adhesive emulsion for medical purposes made from ethylene-vinyl acetate copolymers and adhesive resins |
| 02/04/2004 | EP1385489A1 Coated granules based on angiotensin-converting enzyme inhibitor |
| 02/04/2004 | EP1385486A1 A novel coating for a sustained release pharmaceutical composition |